Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions
AbstractDNA polymerases are essential for genome replication, DNA repair and translesion DNA synthesis (TLS). Broadly, these enzymes belong to two groups: replicative and non-replicative DNA polymerases. A considerable body of data suggests that both groups of DNA polymerases are associated with cancer. Many mutations in cancer cells are either the result of error-prone DNA synthesis by non-replicative polymerases, or the inability of replicative DNA polymerases to proofread mismatched nucleotides due to mutations in 3′-5′ exonuclease activity. Moreover, non-replicative, TLS-capable DNA polymerases can negatively impact cancer treatment by synthesizing DNA past lesions generated from treatments such as cisplatin, oxaliplatin, etoposide, bleomycin, and radiotherapy. Hence, the inhibition of DNA polymerases in tumor cells has the potential to enhance treatment outcomes. Here, we review the association of DNA polymerases in cancer from the A and B families, which participate in lesion bypass, and conduct gene replication. We also discuss possible therapeutic interventions that could be used to maneuver the role of these enzymes in tumorigenesis. View Full-Text
Share & Cite This Article
Shanbhag, V.; Sachdev, S.; Flores, J.A.; Modak, M.J.; Singh, K. Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. Biology 2018, 7, 5.
Shanbhag V, Sachdev S, Flores JA, Modak MJ, Singh K. Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. Biology. 2018; 7(1):5.Chicago/Turabian Style
Shanbhag, Vinit; Sachdev, Shrikesh; Flores, Jacqueline A.; Modak, Mukund J.; Singh, Kamalendra. 2018. "Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions." Biology 7, no. 1: 5.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.